Immunex/Hoechst CSF research agreement
Executive Summary
Immunex expanding research agreement with the Hoechst subsidiary, Behringwerke, to include additional colony stimulating factors (CSFs). Immunex began work with Behringwerke in mid-1984 and has one CSF protein (GM-CSF) headed for clinical trials "in early 1986." The colony stimulating factors covered by the new agreement "include granulocyte CSF, macrophage CSF, Hemopoietin-1, and Burst Promoting Activity".
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.